11,964 results match your criteria vasomotor symptoms


Pharmacotherapeutic options for the treatment of menopausal symptoms.

Expert Opin Pharmacother 2021 May 13:1-19. Epub 2021 May 13.

Division of Obstetrics and Gynecology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

: Menopausal symptoms can be very overwhelming for women. Over the years, many pharmacotherapeutic options have been tested, and others are still being developed. Hormone therapy (HT) is the most efficient therapy for managing vasomotor symptoms and related disturbances. Read More

View Article and Full-Text PDF

What Is the Role of Assessing Ischemia to Optimize Therapy and Outcomes for Patients with Stable Angina and Non-obstructed Coronary Arteries?

Cardiovasc Drugs Ther 2021 May 12. Epub 2021 May 12.

Division of Cardiovascular Medicine, University of Florida, Gainesville, FL, USA.

Ischemic heart disease (IHD) is a leading global cause of ill-health and premature death. Clinical research into IHD is providing new insights into the pathophysiology, epidemiology and treatment of this condition. The major endotypes of IHD include coronary heart disease (CHD) and vasomotor disorders, including microvascular angina and vasospastic angina. Read More

View Article and Full-Text PDF

Predictive and criterion validity of the Cervantes-SF menopause quality of life questionnaire.

Menopause 2021 May 10. Epub 2021 May 10.

Women's Health Institute, San Carlos Clinic Hospital, IdISSC, Complutense University, Madrid, Spain Faculty of Psychology, Autonoma University of Madrid, Madrid, Spain Department of Obstetrics and Gynecology, Sanitas La Zarzuela Hospital, Francisco de Vitoria University, Madrid, Spain Department of Obstetrics and Gynecology, Miguel Servet Hospital, Zaragoza, Spain Department of Obstetrics and Gynecology, School of Medicine, University of Granada, Spain Department of Obstetrics and Gynecology, Central Hospital of Asturias, University of Oviedo, Spain Department of Pharmacoeconomics and Health Outcomes Research, Pfizer SLU, Alcobendas, Madrid, Spain.

Objectives: To determine the predictive and criterion-based validity of the Cervantes-SF scale that measures the impact of menopause on Health-Related Quality of Life.

Methods: We recruited a noninstitutionalized sample of peri/postmenopausal women aged 40 to 65 years, who had their last menstrual cycle 12+ months prior to inclusion in the study of the psychometric validity of the Cervantes-SF scale. Predictive validity of the scale was confirmed for various health outcome measures administered concomitantly (years of disability-free life expectancy, work productivity and impact on daily activities, economic impact arising from loss of work productivity, hours of undisturbed sleep each day, and the utilization of healthcare facilities), whilst criterion validity was determined by the likelihood of identifying a moderate-to-severe vasomotor or genital syndrome requiring specific treatment. Read More

View Article and Full-Text PDF

Quantification of Absolute Myocardial Flow and Resistance by Continuous Thermodilution in Patients with Ischemia and Nonobstructive Coronary Artery Disease (INOCA).

J Vis Exp 2021 Apr 24(170). Epub 2021 Apr 24.

Radboud University Medical Center;

In approximately half of the patients undergoing coronary angiography for angina pectoris or for signs or symptoms suggestive of ischemic heart disease, no obstructive coronary artery disease is angiographically visible. The majority of these patients with angina or ischemia and no obstructive coronary artery disease (INOCA) have an underlying coronary vasomotor dysfunction, and current consensus documents recommend diagnostic invasive coronary vasomotor function testing (CFT). During CFT, a variety of vasomotor dysfunction endotypes can be assessed, including vasospastic coronary dysfunction (epicardial or microvascular vasospasm), and/or microvascular vasodilatory dysfunction, including impaired vasodilatory capacity and increased microvascular resistance. Read More

View Article and Full-Text PDF

Case of cholestatic drug-induced liver injury (DILI) associated with black cohosh.

BMJ Case Rep 2021 May 7;14(5). Epub 2021 May 7.

Internal Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA.

Drug-induced liver injury is an uncommon yet fatal cause of liver injury. Black cohosh is a herbal supplement that is derived from It has been used for vasomotor symptoms in postmenopausal women, but it can cause liver injury. A 50-year-old Afro-American woman presented with a 2-month history of malaise, itching and severe jaundice. Read More

View Article and Full-Text PDF

Syncope associated with supraventricular tachycardia: Diagnostic role of implantable loop recorders.

Ann Noninvasive Electrocardiol 2021 May 6:e12850. Epub 2021 May 6.

First Department of Cardiology, School of Medicine, Hippokration General Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Syncope represents a relatively uncommon symptom of supraventricular tachycardia (SVT). It is likely that an impaired autonomic vasomotor response to the hemodynamic stress of tachycardia is the determinant of hemodynamic changes leading to cerebral hypoperfusion and syncope. In this regard, tilt-table test may detect abnormalities in the autonomic nervous function and predict the occurrence of syncope during SVT. Read More

View Article and Full-Text PDF

Menopausal osteoporosis: screening, prevention and treatment.

Singapore Med J 2021 Apr;62(4):159-166

Department of Obstetrics and Gynaecology, National University Hospital, Singapore.

Screening for osteoporosis in women can be based on age and weight, using the Osteoporosis Screening Tool for Asians and assessment for other risk factors such as early menopause, Chinese ethnicity and other secondary factors. Based on the resulting risk profile, women can be triaged to dual-energy X-ray absorptiometry (DEXA) scanning for definite diagnosis of osteoporosis. Treatment should be considered in women with previous fragility fractures, DEXA-diagnosed osteoporosis and high risk of fracture. Read More

View Article and Full-Text PDF

Updates on Therapeutic Alternatives for Genitourinary Syndrome of Menopause: Hormonal and Non-Hormonal Managements.

J Menopausal Med 2021 Apr;27(1):1-7

Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Postmenopausal atrophic vaginitis, along with vasomotor symptoms and sleep disorders, is one of the most troublesome symptoms of menopause. However, many women do not manage this symptom properly due to insufficient knowledge of the symptoms or sexual embarrassment. With appropriate treatment, many postmenopausal women can experience relief from discomforts, including burning sensation or dryness of the vagina and dyspareunia. Read More

View Article and Full-Text PDF

Machine Learning Approaches to Identify Factors Associated with Women's Vasomotor Symptoms Using General Hospital Data.

J Korean Med Sci 2021 May 3;36(17):e122. Epub 2021 May 3.

Department of Obstetrics & Gynecology, Korea University College of Medicine, Seoul, Korea.

Background: To analyze the factors associated with women's vasomotor symptoms (VMS) using machine learning.

Methods: Data on 3,298 women, aged 40-80 years, who attended their general health check-up from January 2010 to December 2012 were obtained from Korea University Anam Hospital in Seoul, Korea. Five machine learning methods were applied and compared for the prediction of VMS, measured by the Menopause Rating Scale. Read More

View Article and Full-Text PDF

The effects of estrogens on neural circuits that control temperature.

Endocrinology 2021 May 3. Epub 2021 May 3.

Department of Integrative Biology and Physiology, University of California Los Angeles, CA, USA.

Declining and variable levels of estrogens around the time of menopause are associated with a suite of metabolic, vascular, and neuroendocrine changes. The archetypal adverse effects of peri-menopause are vasomotor symptoms, which include hot flashes and night sweats. Although vasomotor symptoms are routinely treated with hormone therapy, the risks associated with these treatments encourage us to seek alternative treatment avenues. Read More

View Article and Full-Text PDF

Which Hormones and Contraception for Women with APS? Exogenous Hormone Use in Women with APS.

Curr Rheumatol Rep 2021 Apr 30;23(6):44. Epub 2021 Apr 30.

Weill Cornell Medicine, New York, NY, 10021, USA.

Purpose Of Review: Use of exogenous estrogen carries significant risk for patients with prothrombotic disorders including those with antiphospholipid antibody (aPL) and antiphospholipid syndrome (APS). This review summarizes current knowledge of contraceptive and other hormone therapies for aPL-positive and APS women and highlights knowledge gaps to guide future research.

Recent Findings: Studies support very low risk for most progestin-only contraceptives in patients with increased thrombotic risk, but suggest increased VTE risk with depot-medroxyprogesterone acetate. Read More

View Article and Full-Text PDF

A core outcome set for vasomotor symptoms associated with menopause: the COMMA (Core Outcomes in Menopause) global initiative.

Menopause 2021 Apr 26. Epub 2021 Apr 26.

Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, Australia Obstetrics and Gynaecology, Eastern Virginia Medical School, Norfolk, VA Women's Health Research Program, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia School of Nursing, Indiana University, Indianapolis, IN Department of Obstetrics and Gynaecology, University of Chicago, Chicago, IL Red Hot Mamas North America, Inc, Town of Ridgefield, CT Obstetrics and Gynecology, New York University School of Medicine, New York, NY Department of Obstetrics and Gynaecology, University Hospitals Dorset NHS Trust, Poole, Dorset, UK Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK Centre for Women's Health, Institute of Population Health Sciences, Queen Mary University London, London, UK Department of Obstetrics and Gynaecology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand Connors Center for Women's Health and Gender Biology and the Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA Department of Obstetrics and Gynaecology, Fortis Escort Hospital, Jaipur, India Department of Gynaecology and Obstetrics, University of Muenster, Muenster, Germany Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia Amsterdam Reproduction and Development, Center for Reproductive Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands Department of Reproductive and Maternal medicine, School of Medicine, University of Glasgow, Glasgow, UK University of Illinois at Chicago, Departments of Psychiatry, Psychology and Obstetrics and Gynecology, Chicago, IL Research Center for Reproductive Medicine, Gynecological Endocrinology and Menopause, IRCCS San Matteo Foundation, Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy Queen Charlotte's and Chelsea and Chelsea and Westminster Hospitals, Imperial College London, London, UK Auckland District Health Board, Auckland, New Zealand Midlife Women's Health Center, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA Department of Obstetrics and Gynecology, George Washington University, Washington, DC Monash Centre for Health Research and Implementation, School of Public Health and Preventive Medicine, Monash University, Clayton, Victoria, Australia Department of Obstetrics and Gynaecology, University of Toronto, Toronto, Canada.

Objective: Vasomotor symptoms (VMS) (hot flashes and night sweats) affect most women over the menopause transition. Comparing the safety and effectiveness of treatments for vasomotor symptoms is limited by the use of inconsistent outcome measures, and uncertainty as to which outcomes are most important to symptomatic women. To address this, we have developed a Core Outcome Set (COS) for use in clinical trials of treatments for VMS. Read More

View Article and Full-Text PDF

Genetic variants predictive of reproductive aging are associated with vasomotor symptoms in a multiracial/ethnic cohort.

Menopause 2021 Apr 26. Epub 2021 Apr 26.

Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA Department of Nutritional Sciences, School of Public Health, University of Michigan, Ann Arbor, MI.

Objective: Vasomotor symptoms (VMS), hot flashes, and night sweats are cardinal symptoms of the menopausal transition. Little is known about genetic influences on VMS. This study evaluated whether previously identified genetic factors predictive of VMS, age at menarche, and age at menopause were associated with VMS in a multiracial/ethnic cohort. Read More

View Article and Full-Text PDF

Qualitative study: burden of menopause-associated vasomotor symptoms (VMS) and validation of PROMIS Sleep Disturbance and Sleep-Related Impairment measures for assessment of VMS impact on sleep.

J Patient Rep Outcomes 2021 Apr 26;5(1):37. Epub 2021 Apr 26.

RTI Health Solutions, Patient-Centered Outcomes Assessment Group, Research Triangle Park, NC, USA.

Purpose: We evaluated the impact of menopause-associated vasomotor symptoms (VMS) on sleep. We also sought to establish the content validity of Patient-Reported Outcomes Measurement Information System (PROMIS) short form Sleep-Related Impairment and Sleep Disturbance measures in postmenopausal women with moderate to severe VMS.

Methods: Cross-sectional, in-person, qualitative interviews were conducted in the United States (Texas, Illinois) and European Union (UK, France) with women aged 40-64 years experiencing moderate to severe VMS (≥35/wk). Read More

View Article and Full-Text PDF

Alcohol and Breast Cancer: Results From the Women's Wellness After Cancer Program Randomized Controlled Trial.

Cancer Nurs 2021 Apr 20. Epub 2021 Apr 20.

Author Affiliations: School of Nursing, Midwifery and Social Work, The University of Queensland, Brisbane (Drs Balaam, Bailey, and McCarthy); University of Technology Sydney, Ultimo, New South Wales (Dr Anderson); School of Public Health, The University of Queensland, Brisbane (Dr Retell); Mater Research Institute, Mater Health Services, South Brisbane (Dr McCarthy), Queensland, Australia.

Background: There is evidence that drinking alcohol increases the risk of recurrent breast cancer. It is unclear whether Australian women with breast cancer are aware of this evidence or modify their alcohol intake accordingly.

Objective: This article reports a secondary analysis of data from the Women's Wellness after Cancer Program (WWACP) randomized controlled trial (N = 351). Read More

View Article and Full-Text PDF

Modified impression technique for extreme mouth-opening limitation caused by systemic scleroderma.

Quintessence Int 2021 Apr 21;0(0). Epub 2021 Apr 21.

Systemic scleroderma is a relatively rare, autoimmune, chronic, and debilitating disease, and its etiology is unknown. The disease is characterized by vasomotor disturbances causing skin and mucosa hardening, hand stiffness, excess production of collagen fibers, and impairment of the internal organs associated with the immune system. Extreme mouth-opening limitation is one of the symptoms in the oral cavity, and compromises dental intervention. Read More

View Article and Full-Text PDF

Peripheral vasoreactivity in acute ischemic stroke with hemiplegia.

Sci Rep 2021 Apr 20;11(1):8531. Epub 2021 Apr 20.

Department of Neurology, Jeonbuk National University Medical School and Hospital, 20 Geonji-ro, Deokjin-gu, Jeonju, 54907, Republic of Korea.

The association between vasomotor tone of the peripheral arteries and cerebral hemisphere function has not been established. This study analyzed the peripheral vasoreactivity of patients with acute ischemic stroke and hemiplegia using a modified Raynaud scan, which is a new technology for blood flow measurement. In this retrospective case-control study, we examined patients with unilateral weakness consistent with ischemic lesions who underwent brain magnetic resonance imaging and modified Raynaud scanning within five days from the onset of symptoms. Read More

View Article and Full-Text PDF

Recommended Hormone Therapy in Menopause: Concepts, Controversies and Approach to Treatment.

Endocr Rev 2021 Apr 15. Epub 2021 Apr 15.

Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 900 Commonwealth Avenue, Boston, Massachusetts USA.

Hormone therapy (HT) is an effective treatment for menopausal symptoms, including vasomotor symptoms and genitourinary syndrome of menopause. Randomized trials also demonstrate positive effects on bone health, and age-stratified analyses indicate more favorable effects on coronary heart disease and all-cause mortality in younger women (close proximity to menopause) than in women more than a decade past menopause. In the absence of contraindications or other major comorbidities, recently menopausal women with moderate or severe symptoms are appropriate candidates for HT. Read More

View Article and Full-Text PDF

Predicting the age at natural menopause in middle-aged women.

Menopause 2021 Apr 12. Epub 2021 Apr 12.

Gerontology Research Center and Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland Department of Mathematics and Statistics, University of Jyväskylä, Jyväskylä, Finland Department of Obstetrics and Gynecology, Pelvic Floor Research and Therapy Unit, Central Finland Central Hospital, Jyväskylä, Finland LIKES Research Centre for Physical Activity and Health, Jyväskylä, Finland Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland.

Objective: To predict the age at natural menopause (ANM).

Methods: Cox models with time-dependent covariates were utilized for ANM prediction using longitudinal data from 47 to 55-year-old women (n = 279) participating in the Estrogenic Regulation of Muscle Apoptosis study. The ANM was assessed retrospectively for 105 women using bleeding diaries. Read More

View Article and Full-Text PDF

Managing Common Estrogen Deprivation Side Effects in HR+ Breast Cancer: an Evidence-Based Review.

Curr Oncol Rep 2021 Apr 14;23(6):63. Epub 2021 Apr 14.

Oncology Center, Hospital Moinhos de Vento, R. Tiradentes, 333, Porto Alegre, RS, 90560-030, Brazil.

Purpose Of Review: The article reviews the consequences of estrogen deprivation during endocrine therapy for breast cancer and provides an update on alternative therapies for the management of symptoms.

Recent Findings: Endocrine therapy has progressed substantially in recent years, and its use is recommended for all breast cancer patients expressing hormone receptors. The main adverse events of this treatment can be controlled with medications and nonpharmacological measures. Read More

View Article and Full-Text PDF

Traditional Korean medicine treatment for tamoxifen associated adverse events of breast cancer patient: A CARE - Compliant case report.

Complement Ther Clin Pract 2021 May 2;43:101378. Epub 2021 Apr 2.

Chung-Yeon Central Institute, 64, Sangmujungang-ro, Seo-gu, Gwangju, 61949, Republic of Korea. Electronic address:

Background: Adverse events of endocrine therapy reduce the breast cancer patient's quality of life and adversely affect treatment compliance.

Method: A 50-year-old breast cancer patient complained of several symptoms such as hot flush, hyperhidrosis, urinary frequency, and depression. These symptoms occurred after taking tamoxifen. Read More

View Article and Full-Text PDF

Risks, Benefits, and Treatment Modalities of Menopausal Hormone Therapy: Current Concepts.

Front Endocrinol (Lausanne) 2021 26;12:564781. Epub 2021 Mar 26.

Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States.

Menopausal hormone therapy (HT) prescribing practices have evolved over the last few decades guided by the changing understanding of the treatment's risks and benefits. Since the Women's Health Initiative (WHI) trial results in 2002, including post-intervention analysis and cumulative 18-year follow up, it has become clear that the risks of HT are low for healthy women less than age 60 or within ten years from menopause. For those who are experiencing bothersome vasomotor symptoms, the benefits are likely to outweigh the risks in view of HT's efficacy for symptom management. Read More

View Article and Full-Text PDF

[Differential diagnosis of vasomotor symptoms. Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines].

Gynecol Obstet Fertil Senol 2021 May 8;49(5):329-334. Epub 2021 Apr 8.

Unité de gynécologie médicale, hôpital Port-Royal, 123, boulevard de Port-Royal, 75014 Paris, France.

Hormone replacement therapy (HRT) significantly decreases the frequency and intensity of vasomotor symptoms (VMS). It is recommended to evaluate clinical efficacy of HRT on VMS. The absence of reduction in VMS after adaptation of the modalities of the HRT suggests the possibility of atypical VMS. Read More

View Article and Full-Text PDF

Pharmacologic and hormonal treatments for menopausal sleep disturbances: A network meta-analysis of 43 randomized controlled trials and 32,271 menopausal women.

Sleep Med Rev 2021 Mar 11;57:101469. Epub 2021 Mar 11.

Institute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung, Taiwan. Electronic address:

This network meta-analysis aimed at investigating efficacy/tolerability of pharmacologic/hormonal interventions for menopausal sleep disturbances. Major databases were searched for randomized controlled trials (RCTs) examining pharmacologic or hormonal interventions with either placebo or active controlled designs. Primary outcomes were improvements in sleep disturbance severity/tolerability (i. Read More

View Article and Full-Text PDF

[The efficacy of the anti-acidemic agent dimephosphone at the first rehabilitation stage in patients in the acute period of carotid-related ischemic stroke].

Zh Nevrol Psikhiatr Im S S Korsakova 2021 ;121(3):44-51

Kazan State Medical University, Kazan, Russia.

Objective: To evaluate the efficacy of the intravenous form of dimephosphon at the first stage of rehabilitation in patients with ischemic stroke in the carotid system.

Material And Methods: The article presents the results of examination of 60 patients in the acute period of ischemic stroke in the carotid system (30 patients were treated with dimephosphon and 30 patients were in the comparison group). The dynamics of the clinical picture (according to the NIHSS), functional dependence in self-service (according to the modified Rankin scale), state of autonomic response using spectral analysis of heart rate variability, cerebrovascular reactivity using functional tests were assessed during the treatment. Read More

View Article and Full-Text PDF

Lowered progesterone metabolite excretion and a variable LH excretion pattern are associated with vasomotor symptoms but not negative mood in the early perimenopausal transition: Study of Women's Health Across the Nation.

Maturitas 2021 May 5;147:26-33. Epub 2021 Mar 5.

Center for Health and the Environment, University of California Davis, Davis, CA, United States.

Objective: The menopausal transition is characterized by progressive changes in ovarian function and increasing circulating levels of gonadotropins, with some women having irregular menstrual cycles well before their final menstrual period. These observations indicate a progressive breakdown of the hypothalamic-pituitary-ovarian axis often associated with an increase in menopausal symptoms. Relationships between vasomotor symptoms (VMS) and depressed mood and sleep as well as a bidirectional association between VMS and depressed mood in mid-life women have been reported, but the endocrine foundations and hormone profiles associated with these symptoms have not been well described. Read More

View Article and Full-Text PDF

Chronic Coronary Syndromes in Women: Challenges in Diagnosis and Management.

Authors:
Matthias R Meyer

Mayo Clin Proc 2021 04;96(4):1058-1070

Division of Cardiology, Triemli Hospital, Zurich, Switzerland; Division of Gender Medicine, Institute of Primary Care, University of Zurich, Switzerland. Electronic address:

Sex matters in science. This particularly applies to ischemic heart disease, which displays key differences in pathophysiology, presentation, and effectiveness in diagnostic strategies and management between women and men. However, underrepresentation of women in randomized trials has led to an evidence gap in clinical practice. Read More

View Article and Full-Text PDF

Utilization of Isoflavones in Soybeans for Women with Menopausal Syndrome: An Overview.

Int J Mol Sci 2021 Mar 22;22(6). Epub 2021 Mar 22.

Department of Obstetrics and Gynecology, Taipei Tzu-Chi Hospital, The Buddhist Tzu-Chi Medical Foundation, Taipei 231, Taiwan.

Based on their nutrient composition, soybeans and related foods have been considered to be nutritious and healthy for humans. Particularly, the biological activity and subsequent benefits of soy products may be associated with the presence of isoflavone in soybeans. As an alternative treatment for menopause-related symptoms, isoflavone has gained much popularity for postmenopausal women who have concerns related to undergoing hormone replacement therapy. Read More

View Article and Full-Text PDF

Autoimmune Diseases in Patients with Premature Ovarian Insufficiency-Our Current State of Knowledge.

Int J Mol Sci 2021 Mar 5;22(5). Epub 2021 Mar 5.

Department of Gynecological Endocrinology, Poznan University of Medical Sciences, 60-535 Poznan, Poland.

Premature ovarian insufficiency (POI), previously known as premature ovarian failure or premature menopause, is defined as loss of ovarian function before the age of 40 years. The risk of POI before the age of 40 is 1%. Clinical symptoms develop as a result of estrogen deficiency and may include amenorrhea, oligomenorrhea, vasomotor instability (hot flushes, night sweats), sleep disturbances, vulvovaginal atrophy, altered urinary frequency, dyspareunia, low libido, and lack of energy. Read More

View Article and Full-Text PDF

Management of Early Menopause/Premature Ovarian Insufficiency in Women with or at High Risk of Breast Cancer.

Semin Reprod Med 2020 Sep 31;38(4-05):309-314. Epub 2021 Mar 31.

Royal Women's Hospital, Parkville, Victoria Australia.

The global incidence of breast cancer is increasing, as is the efficacy of treatments. Consequently, increasing survival rates reinforce the importance of survivorship issues, including posttreatment menopausal symptoms, sexual function, and mental health and well-being. Breast cancer patients can experience a range of menopausal symptoms associated with their treatment. Read More

View Article and Full-Text PDF
September 2020